SA EMS ROAD EXPERIENCE • HPCSA STATUTORY DRUG MONOGRAPH
CLOPIDOGREL BISULFATE
Clopidogrel Bisulfate (Brand Names: Plavix, Clopivas)
HPCSA CDST 2024 (Version 1.3 Framework)
Official Statutory Clinical Reference
Thienopyridine Antiplatelet • Irreversible P2Y12 ADP Receptor Antagonist • Dual Antiplatelet Therapy (DAPT)HPCSA CDST 2024 (v1.3 Framework)
•
CLOPIDOGREL BISULFATE
Clopidogrel Bisulfate (Brand Names: Plavix, Clopivas)
Clinical Summary: A second-generation thienopyridine prodrug that irreversibly blocks platelet P2Y12 ADP receptors to inhibit arterial platelet aggregation in acute STEMI and NSTE-ACS.
Authorized HPCSA Emergency Care Scope of Practice (Annexure A 2022)Statutory Board Mandate
LEGENDARY CCA (^) [ANT PARAMEDIC]NDIP EMC (^) [ANT PARAMEDIC]ECP ONLY (~)
CLOPIDOGREL BISULFATE Audio BriefingCLINICAL PROFESSOR
No Audio Published Yet
00:00Full Monograph
1. Mechanism of Action
How this drug operates physiologically in the human body
2. Statutory Clinical Indications
1 UsesStrictly per HPCSA CDST v1.3, Annexure A & CPG
3. Adverse Effects & Pathophysiology
Why the body reacts and why it occurs in specific indications
4. Contraindications & Lethal Risks
Biological consequences & why it threatens life
5. Statutory Resources & Quotes
Verbatim regulatory excerpts with deep external links
SA EMS FIELD PROTOCOLS • EDUCATIONAL REVIEW & STATUTORY CITATIONS
An independent educational review and study companion based on the official HPCSA CDST 2024 (Version 1.3 Framework), CPG 2018, and Annexure A (2022) sourced directly from the official HPCSA publication portal. Not for live on-scene patient management.
Author: Jacoline (Jax) Geldenhuys, BEMC • HPCSA Registered Emergency Care Practitioner (ECP)